NBTX Stock Overview
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Nanobiotix S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €6.67 |
| 52 Week High | €11.00 |
| 52 Week Low | €4.55 |
| Beta | 1.25 |
| 1 Month Change | 10.98% |
| 3 Month Change | -9.74% |
| 1 Year Change | 27.05% |
| 3 Year Change | -56.12% |
| 5 Year Change | n/a |
| Change since IPO | -60.72% |
Recent News & Updates
Recent updates
Nanobiotix enters final agreement to restructure existing loan with EU's investment bank
Oct 18Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M
Sep 28Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank
Sep 12French biotech Nanobiotix rebounds to post best ever 47% intraday gain
Aug 01Nanobiotix names Bart Van Rhijn as chief financial officer
Jun 01Nanobiotix Will Disrupt Oncological Radiotherapy
Jan 29Shareholder Returns
| NBTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 10.2% | 1.3% | 3.3% |
| 1Y | 27.0% | 3.0% | 25.0% |
Return vs Industry: NBTX exceeded the US Biotechs industry which returned 3% over the past year.
Return vs Market: NBTX exceeded the US Market which returned 25% over the past year.
Price Volatility
| NBTX volatility | |
|---|---|
| NBTX Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NBTX has not had significant price volatility in the past 3 months.
Volatility Over Time: NBTX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 102 | Laurent Levy | www.nanobiotix.com |
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
Nanobiotix S.A. Fundamentals Summary
| NBTX fundamental statistics | |
|---|---|
| Market cap | US$315.09m |
| Earnings (TTM) | -US$42.76m |
| Revenue (TTM) | US$39.00m |
8.0x
P/S Ratio-7.3x
P/E RatioIs NBTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBTX income statement (TTM) | |
|---|---|
| Revenue | €36.21m |
| Cost of Revenue | €0 |
| Gross Profit | €36.21m |
| Other Expenses | €75.91m |
| Earnings | -€39.70m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 100.00% |
| Net Profit Margin | -109.64% |
| Debt/Equity Ratio | -2,467.9% |
How did NBTX perform over the long term?
See historical performance and comparison